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Objective: We aimed to determine the effectiveness of natalizumab (NTZ) by assessing
overall No Evidence of Disease Activity 3 (NEDA-3) in a local Norwegian cohort.
Background: NTZ is an immunomodulating drug used in the treatment of multiple
sclerosis (MS). It has typically been used as a second-line treatment, but certain patients
with high disease activity have started directly with NTZ.
Methods: This retrospective cohort study includes all patients who received NTZ for
relapsing–remitting MS at Nordland Hospital in the period 2008–2018. In June 2019,
status for every patient was assessed, and a survival curve was used to show the
cumulative probability of achieving NEDA-3 over time.
Results: The cohort consisted of 66 patients, 49 women and 17 men with a mean
age of 40.0 ± 10.8 years. Each patient received on average 45.8 ± 36.4 NTZ infusions.
Mean age and Expanded Disability Status Scale (EDSS) at first infusion was 34.8 ± 10.5
and 3.2 ± 1.9, respectively. Prior to NTZ treatment, 83% had used other disease
modulating drugs and 65% were anti-JC virus (JCV) seronegative. During the study
period, seven patients converted to seropositive. In 2019, 40 patients had switched or
stopped treatment: 19 due to positive JCV serostatus, 9 due to disease activity, 7 due
to adverse effects or complications (1 progressive multifocal leukoencephalopathy), 2
due to pregnancy, and 3 due to autologous hematopoietic cell transplantation abroad.
Three patients experienced rebound in the wake of discontinuation (7.5%). Of the patients
receiving NTZ for more than 3 years (n = 33), 50% had achieved NEDA-3 after 3 years.
Compared to those with evidence of disease activity (EDA), these NEDA-3 patients had
significant lower EDSS score before first NTZ treatment (p= 0.04). They were also slightly,
but not significantly, younger at debut of their MS, at the diagnosis and at first NTZ
treatment. Of all the patients who ever started on NTZ, 23% had achieved NEDA-3 5
years later. The mean EDSS in 2019 was 3.6 ± 2.5.
Conclusion: Despite the high rate of treatment switch, mainly due to the risk of PML,
almost one in four who started on NTZ achieved NEDA-3 after 5 years, and the overall
disease progression was low in the total cohort. Treating less advanced disease seems
to predict better long-term stability.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic disease characterized by
inflammatory lesions in the central nervous system (CNS). It
is regarded as the most common cause of neurologic deficits
in young adults (1). A fluctuating process of inflammation,
typically seen early in the disease, clinically manifested with
transient episodes of neurological symptoms (relapsing–
remitting multiple sclerosis, RRMS), affects the majority. As
the disease progresses over time, CNS lesions are accumulating,
neurodegeneration becomes more evident, and patients
progress to a higher disability (2). Traditionally, the Expanded
Disability Status Scale (EDSS) (3) has been used to assess
disease progression.
Natalizumab (NTZ) is a monoclonal antibody approved as
a treatment for RRMS (4). Due to safety concerns, particularly
an increased risk of progressive multifocal leukoencephalopathy
(PML), treatment has generally been reserved for patients
with highly active disease. Most often, NTZ has been given if
initial therapy was considered ineffective or poorly tolerated,
but sometimes also as initial therapy in aggressive disease.
Recently, Beslutningsforum (a decision forum established by
The Norwegian Ministry of Health and Care Services) decided
that NTZ treatment cannot be initiated in new patients after
December 1, 2019.
In the Tysabri Observational Program (TOP), 86.5% of
patients, with a median EDSS score of 3.5, did not experience
EDSS increases ≥ 1.0 after 24 months of NTZ treatment (5).
Besides the TOP data, which are based on active registration and
patient consent, relatively few studies have described complete
cohorts with real-world data. In recent years, No Evidence of
Disease Activity (NEDA) has been used as a surrogate outcome
measure in clinical treatment trials (6). We set out to describe all
patients treated with NTZ over a 10-year period at a single center,
and assess NEDA-3 over time.
METHOD
Patients
All patients with relapsing–remitting MS diagnosed in
accordance with the McDonald criteria (7), receiving at
least one dose of NTZ at Nordland hospital in the period
2008–2018 were included in this study. The patients received
intravenous infusions with 300mg NTZ every 4 weeks. None
of the patients were on extended interval dosing regimen. Side
effects were reported to specialized nurses at every infusion and
at every outpatient visit (every 6–12 months) carried out by
a neurologist.
Time and Location
This study took place at Nordland Hospital localized in the
northern part of Norway. On January 1, 2017, there were 657
patients living with MS out of a population of 242,866 in
Nordland (7). All patients with MS treated with NTZ at the
hospital, from the first patient in 2008 until June 2018, were
included. A final status assessment was made in June 2019.
Data Acquisition
The patients were identified and scrutinized through an
electronic medical record system (DIPS) at the hospital. All
patients had been examined by a neurologist or a doctor in
training for becoming a neurologist 3 months after the first
NTZ infusion, and later every 6–12 months. MRI scans were
carried out prior to the patient’s appointments. EDSS score was
calculated retrospectively by the investigators when missing in
the medical recordings. If patients had moved during the follow-
up period and treated elsewhere, medical records from their
current hospital were obtained. The variables recorded for every
study patient are listed in Tables 1–4.
Primary Outcome
NEDA-3, a well-accepted outcome measure to assess disability
and prognosis in RRMS (8), was the primary outcome of the
study. A status of NEDA-3 is based on (1) absence of clinical
MS relapse, (2) absence of disability worsening corresponding
to ≥1 point increase in EDSS sustained for 6 months, and (3)
absence of gadolinium-enhancing lesions or new or enlarged T2-
hyperintense lesions on magnetic resonance imaging (MRI) (9).
Secondary Outcomes
Secondary outcomes included adverse effects of NTZ and causes
of drug abruption and switch of treatment. We also searched for
differences between those with evidence of disease activity (EDA)
and those who achieved NEDA-3.
Statistical Analysis
A survival curve was used to demonstrate the cumulative
probability of having NEDA-3 status over time. The Kaplan–
Meier survival method was used to compare the survival curves
for males and females. Student’s t-test was applied to compare
demographic data. The threshold for statistical significance was
p < 0.05. Secondary outcomes are descriptively presented. IBM
SPSS statistics version 26 was used for all the analyses.
Study Approval
The study was approved by the institutional data protection
official (PVO 03-18).
RESULTS
Demographics and Diagnostic Data
A total of 66 patients with RRMS were treated at Nordland
hospital with at least one dose of NTZ in the given study period
(Table 1). The cohort consisted of 49 women and 17 men with
mean age of 40.0 ± 10.8 years as of 2019. The mean age at
diagnosis was 28.9± 9.3 years. The mean EDSS score at the time
of diagnosis was 2.2±1.6. It took on average 1.8± 3.6 years from
the first symptom of MS until diagnosis.
Treatment With NTZ
Mean age and EDSS of the patients at first infusion were 34.8
±10.5 years and 3.2± 1.9, respectively (Table 2).
Prior to treatment, 43 (65%) were anti-JC virus (JCV)
seronegative, but 7 of these seroconverted to positive during the
study. On average, each patient received 45.8 ± 36.4 doses of
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TABLE 1 | Demographic and diagnostic data for the MS population.
Women Men Total p-value
(n = 49) (n = 17) (n = 66)
Debut
Age at MS-debut (age),
mean ± SD
27.4 ± 9.4 25.7 ± 10.7 26.9 ± 9.7 0.53
Debut compatible with
posterior myelitis, n (%)
19 (39) 6 (35) 25 (38) 0.83
Debut compatible with optic
neuritis, n (%)
12 (24) 5 (29) 17 (26) 0.79
Diagnosis
Age at diagnosis (years),
mean ± SD
29.2 ± 9.1 27.9 ± 9.9 28.9 ± 9.3 0.63
EDSS at time of diagnosis,
mean ± SD
2.3 ±1.8 2.1 ± 1.1 2.2 ± 1.6 0.71
Leukocytes in CSF at first
examination (n), mean ± SD
10.8 ± 9.5 11.3 ± 12.3 1.0 ± 10.2 0.89
Total protein in CSF at first
examination (n), mean ± SD
0.39 ± 0.14 0.51 ± 0.14 0.42 ± 0.15 0.08
IgG Index in CSF at first
examination, mean ± SD
1.27 ± 0.61 1.18 ± 0.62 1.25 ± 0.61 0.68
Time from diagnosis to first
treatment (years),
mean ± SD
2.1 ± 4.1 0.7 ± 1.7 1.8 ± 3.6 0.05
CSF, cerebrospinal fluid; EDSS, Expanded Disability Status Scale.
NTZ (range 137). Eleven patients (17%) started with NTZ as a
first-line therapy, and 13 (20%) of the patients started with the
treatment within 1 year of the diagnosis. On average, however,
it took 7.9 ± 6.5 years after first symptom and 5.9 ± 5.8 years
after the diagnosis before treatment with NTZ was given. Most
of the patients (55, 83%) had received other disease-modulating
therapies (DMTs) prior to NTZ.
The risk of PML was the main reason for NTZ
discontinuation. Twenty patients changed treatment to
fingolimod, four to alemtuzumab, two to dimethyl fumarate,
five to rituximab, and three patients received autologous
hematopoietic cell transplantation (aHSCT) abroad. The patients
who received aHSCT actually had a stable disease, but still
wanted the treatment. They did it at own costs. Five patients
did not receive any further treatment, and one patient died with
secondary progressive MS. Three patients experienced rebound
subsequent to discontinuation of NTZ.
Survival Analyses
The Kaplan–Meier survival analysis was used to look at disease
activity rates over the study period and to compare the differences
in the proportions in males and females. On average, females
received 50 infusions before disease activity compared with 63 in
males. No significant statistical difference was found (Breslow, p
= 0.50). Figure 1 shows the cumulative risk over time of disease
activity after having started with NTZ treatment.
Side Effects and Tolerability of NTZ
Side effects were recorded in 16 patients (24%). These included
fatigue (n = 5), headache (n = 2), fever (n = 1), hair loss (n
TABLE 2 | Treatment with natalizumab.
Women Men Total p-value




18 (37) 5 (29) 23 (35) 0.79
Patients who have used
DMTs, n (%)
42 (86) 13 (76) 55 (83) 0.38
Drugs (n), mean ± SD 1.2 ± 0.8 1.2 ± 1.0 1.2 ± 0.8 0.95
*Duration of prior DMTs
(years), mean ± SD
3.4 ± 3.4 3.4 ± 3.3 3.4 ± 3.4 0.96
Clinical attacks last 12
months, mean ± SD
1.38 ± 1.0 1.24 ± 0.8 1.34 ± 1.0 0.62
EDSS, mean ± SD 3.3 ± 2.0 2.9 ± 1.5 3.2 ± 1.9 0.43
EDSS < 3.0, n (%) 19 (39) 9 (53) 28 (42) 0.31
Treatment
Age (years) at first dose,
mean ± SD
32.8 ± 10.7 35.5 ± 10.5 34.8 ± 10.5 0.37
Infusions (n), mean ± SD 42.5 ± 33.8 55.3 ± 43.0 45.8 ± 36.4 0.21
Antibodies against
natalizumab, n
1 0 1 0.55
Leukocytosis, n (%) 19 (39) 8 (47) 27 (41) 0.55
JCV-conversion, n (%) 5 (10) 2 (12) 7(11) 0.86
**Reported side-effects,
n (%)
14 (29) 2 (12) 16 (24) 0.16
***NEDA-3 after 1 year, n (%) 37 (76) 12 (71) 49 (74) 0.55
***NEDA-3 after 2 years,
n (%)
33 (67) 12 (71) 45 (68) 0.35
***NEDA-3 after 3 years,
n (%)
21 (43) 11 (65) 33 (50) 0.20
***NEDA-3 after 5 years,
n (%)




disease activity, n (%)
8 (16) 1 (6) 9 (14) 0.28
Discontinuation due to
JCV-status, n (%)
15 (30) 4 (24) 19 (29) 0.58
Discontinuation due to other
causes****, n (%)
10 (20) 2 (12) 12 (18) 0.43
Rebound, n (%) 2 (4) 1 (6) 3 (5) 0.76
EDSS, Expanded Disability Status Scale; NA, Not applicable; JCV, JC polyomavirus;
NEDA-3, No Evidence of Disease Activity, DMD, Diseasemodulating treatment. *Range
13 **Most side effects were mild, but six patients discontinued NTZ because of side
effects; one because of hypersensitivity reaction and one due to progressive multifocal
leukoencephalopathy (PML). ***Number of patients who were treated for the given
years is in parentheses. ****Pregnancy, adverse effects, and self-financed autologous
hematopoietic stem cell transplantation.
= 1), hypertension (n = 1), influenza-like symptoms (n = 1),
muscle cramps (n = 1), increased infection tendency (n = 1),
hypersensitivity reaction (n = 1), myalgia (n = 1), and allergy (n
= 1). One patient developed urticarial rash during an infusion.
Another patient experienced a hypersensitivity reaction during
the third infusion, requiring adrenaline. One patient developed
PML, but recovered with onlyminor sequela. An undernourished
patient with advanced MS died in secondary progressive disease
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TABLE 3 | Differences between patients with EDA and NEDA-3 after 3 years.
EDA NEDA-3 p-value
(n = 33) (n = 33)
Age at MS-debut (age),
mean ± SD
27.6 ± 10.7 26.3 ± 8.7 0.61
Age at diagnosis (years),
mean ± SD
29.5 ± 10.4 28.3 ± 8.1 0.59
Age at first natalizumab dose,
mean ± SD
36.3 ± 11.0 33.6 ± 10.1 0.31
EDSS at time of diagnosis,
mean ± SD
2.3 ± 1.6 2.2 ± 1.6 0.79
EDSS before first natalizumab
treatment, mean ± SD
3.7 ± 2.1 2.7 ± 1.6 0.04
Time from diagnosis to first
treatment (years), mean ± SD
3.4 ± 3.3 3.6 ± 3.5 0.80
Having received natalizumab as
first line treatment, n (%)
6 (18%) 5 (15%) 0.74
EDSS in 2019, mean ± SD 4.5 ± 3.0 2.6 ± 1.6 0.02
EDA, Evidence of Disease Activity; EDSS, Expanded Disability Status Scale; NEDA-3, No
Evidence of Disease Activity.
due to underlying ventricular cancer. Leucocytosis was observed
in 41% of the patients.
Status in 2019
By June 2019, the patients had an average EDSS score of 3.6± 2.5.
A total of eight patients had progressed to secondary progressive
multiple sclerosis (SPMS), all of them women. Thirteen patients
had an EDSS score lower than or equal to that they had
by the time of NTZ start. In total, 40 of the patients had
switched or stopped treatment due to the following reasons:
19 due to positive JCV serostatus, 9 due to disease activity,
7 due to adverse effects or complications (one progressive
multifocal leukoencephalopathy), 2 due to pregnancy, and 3 due
to aHSCT.
Table 2 shows the NEDA-3 status over time. There was
a linear decrease in NEDA-3 during the first 5 years of
treatment before the curve flattened due to low number
of patients remaining on treatment (Figure 1). The overall
proportion of patients having NEDA-3 after 1, 3, and 5
years was found to be 74% (49/66), 50% (33/66), and 23%
(15/66), respectively.
Table 3 shows differences between those who achievedNEDA-
3 after 3 years and those who did not. Lower age at debut,
diagnosis, and at first NTZ treatment in the NEDA-3 group
are noted, but these differences are not significant. EDSS
at first NTZ treatment, however, was significantly lower in
those who achieved NEDA-3 compared to those who had
EDA. Furthermore, the EDSS score in 2019 was significantly
lower in the NEDA-3 group (Table 4). No differences in CSF
investigations before diagnosis and attack frequencies in the last
12 months prior to NTZ treatment were found (calculations
not shown).
TABLE 4 | Status 2019.
Women Men Total p-value
(n = 49) (n = 17) (n = 66)
Age (years), mean ± SD 40.8 ± 10.6 37.5 ± 10.8 40.0 ± 10.8 0.29
*Disease duration (years),
mean ± SD
13.0 ± 7.6 11.1 ± 7.0 12.5 ± 7.5 0.36
EDSS, mean ± SD 3.6 ± 2.5 3.3 ± 2.7 3.6 ± 2.5 0.64
Secondary progressive
disease, n (%)
8 (16) 0 8 (12) 0.08
Still in treatment with
natalizumab, n (%)
16 (20) 10 (59) 26 (43) 0.06
*Time from disease debut to 2019.
DISCUSSION
It is well-known that there seems to be an increased efficacy
of NTZ with longer exposure (10, 11), but the treatment is
limited by the PML risk. The documentation of the long-
term effectiveness (12) is thus limited. In the present study,
we wanted to study success rates, to mirror the results seen
in real-life practice, by using an intention-to-treat approach for
statistical analysis. The major reason for changing treatment in
the present study was not disease activity but JCV status and JCV
seroconversion. Fifteen completed ≥5 years of treatment with
NEDA-3 (23%).
The efficacy after 2 years with a NEDA-3 of 68% was
similar to the findings in other studies. In a recent longitudinal,
retrospective single-cohort study from the Czech Republic,
including 193 patients, more than 70% of patients achieved
NEDA-3 during each year of NTZ treatment after the second
year of treatment (11). In a multicenter study from Italy, the 2-
year proportion of patients withNEDA-3 inNTZ-treated patients
who previously had been non-responders to interferon beta or
glatiramer acetate was 67% (12). In an American observational
study (STRIVE), nearly 75% exhibited NEDA during year 2 of
treatment with NTZ (13).
In our opinion, the effectiveness data in the present study
are good and highly pertinent to real-world decisions in clinical
practice. Almost one in four who started with NZT adhered
to the treatment and showed no disease activity 5 years later.
Despite the high discontinuation rate, and a small risk of rebound
after discontinuation, it is worth noticing that the overall disease
progression in the total cohort, during an average observation
time of 5.2 years, was a mean increase in EDSS of only 0.4.
Whether a shorter use of NTZ, for instance 2 years, may cause
a far longer stabilizing effect in MS can only be speculated since
most patients will switch to another effective treatment after
discontinuation. However, our data show that the patients with
EDA at 3 years were slightly older (not significantly) and had
more advanced disease when they started on NTZ compared to
those who achieved NEDA-3. Their EDSS in 2019 was almost
one point higher than before first treatment with NTZ, while
it was unchanged in those who achieved NEDA-3. This may
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FIGURE 1 | Kaplan-Meier curve for patients with multiple sclerosis (n = 66) achieving NEDA-3 following natalizumab treatment.
indicate that NEDA-3 status predicts both long-term stability
and better prognosis, and that early treatment is associated with
this. Our data are too small to draw a firm conclusion, and
the difference in EDSS in 2019 between the cohorts of patients
with NEDA-3 and EDA at 3 years (2.6 vs. 4.5) could also just
reflect a change in treatment practice—having become more
liberal in treating earlier and more aggressively over the years.
No difference, however, was seen in patients receiving NTZ as
first- or second-line treatment. Our data are, however, too small
to assess this adequately, and also too small to evaluate a potential
effect of previous DMTs.
In general, our long-term data of effectiveness are somewhat
better than found in other studies. In the Czech study, the
cumulative NEDA-3 rate after 2 years was 46%, and after 3 years,
it was 41% (11). In our study, the overall NEDA-3 dropped from
74% from the first year to 68% after the second, and 50% (n= 33)
of our patients had received NEDA-3 after 3 years of treatment.
In the STRIVE interim analyses, 44% attained overall NEDA over
2 years. These were anti-JC virus seronegative patients with early
RRMS (12). In comparison with a Scandinavian cohort study (5),
our patients were slightly younger, had a lower baseline EDSS,
and the NTZ treatment were initiated at a slightly shorter time
after the debut of MS. Our patient population started with NTZ
infusions 7.9 ± 6.5 years after the first symptom and 5.9 ± 5.8
years after the diagnosis. The patients in the real-world study
from Italy started with NTZ 9.3 years after the first symptom
(12). No significant difference in achieving NEDA-3 over time
between males and females was seen in our study. Only one
patient developed antibodies against NTZ. This is lower than
expected. Results from the AFFIRM and the SENTINEL studies
have shown persistent anti-NTZ antibodies in 6%, and such
antibodies have been associated with lower serum concentrations
of NTZ and lower drug effect (14).
Safety data from our study and side effects were as expected
from other studies. In total, 16 (24%) patients reported
side effects. Most were simple headache and fatigue. These
numbers correlate well with numbers from the SENTINEL
study where 20% reported side effects; the most common
was headache (15). Data from the TOP study showed
serious adverse events in 829 of 6,148 patients (13.5%).
The AFFIRM study reported a prevalence of hypersensitivity
reactions <1% and no cases of anaphylactic reactions (15).
One patient in our study developed hypersensitivity reaction
during infusion of NTZ requiring adrenaline. Another patient
developed PML with only minor sequela from that. Other
opportunistic infections can occur during NTZ treatment,
but must be considered rare (16). Such were not seen in
our cohort.
The retrospective nature of the present study, the small sample
size, and the short follow-up time in some of the patients
limit the scientific weight of it. In a few cases, EDSS had
to be calculated retrospectively when missing in the medical
recording, and this must also be regarded a limitation. Applying
a control group and including cognitive function analysis and
brain atrophy measurements (NEDA-4) (17) would certainly
have strengthened the study. However, it provides solid real-
world data from a complete and well-described MS population
(7, 18).
CONCLUSION
The use of NTZ is in real-world practice limited by the risk
of progressive multifocal leukoencephalopathy. It is effective,
however, and it has high tolerability. NTZ should thus remain
an important tool in the medical arsenal against MS.
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